研究Nucleobindin-2(NUCB2)的表現與上尿路上皮癌預後之相關性

吳奕儒 ¹, 李怡琛 ², 李威明 ^3,4,5, 林慧惠^3,6, 徐偉齊 ⁶, 黃阿梅 ^6,7,8, 詹鎮豪^3,7,9

吳文正 ^3,4,6, 李香瑩^4,7,10, 葉信志^3,4,10, 李經家 ^3,4, 柯宏龍 ^3,4,6*

高雄醫學大學附設紀念醫院 不分科¹、 泌尿部²  ; 衛生福利部屏東醫院泌尿科⁴

高雄醫學大學 泌尿學科³、解剖學科⁵ 、醫學研究所⁶、臨床醫學研究所⁷，

生物化學科⁸; 高雄市立小港醫院 泌尿科⁹ ; 高雄市立大同醫院 泌尿科¹⁰

Overexpression of nucleobindin-2(NUCB2) in upper tract urothelial carcinoma

Yi-Ru Wu¹, Yi-Chen Lee ², Wei-Ming Li ^3,4,5, Hui-Hui Lin ^3,6, Wei-Chi Hsu ⁶, A-Mei Huang^6,7,8, Jhen-Hao Jhan^3,7,9, Wen-Jeng Wu ^3,4,6, Hsiang-Ying Lee^4,7,10, Hsin-Chih Yeh^3,4,10, Ching-Chia Li ^{3, 4}, Hung-Lung Ke^2,4,6*

¹  General Division, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

²  Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

³  Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

⁴  Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

⁵  Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan.

⁶  Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

⁷  Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

⁸ Department of Biochemistry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

⁹ Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.

¹⁰ Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.

Purpose: 

Nesfatin-1/Nucleobindin (NUCB2) is mainly expressed in the hypothalamic nuclei and has a proven role in energy homeostasis. NUCB2 is also reported to be aberrantly expressed in several human cancers. However, the precise role of NUCB2 in upper tract urothelial carcinoma (UTUC) has not been studied. In this research, we examined the clinical significance of NUCB2 expression in UTUC.

Materials and methods: 

One hundred and eight formalin-fixed UTUC samples were included in this study. NUCB2 expression was evaluated by immunohistochemistry and the association of NUCB2 expression with different clinicopathological variables was analyzed.

Results:

NUCB-2 expression was significantly correlated with stage (P = 0.001), creatinine level (P = 0.013), recurrence (P = 0.001), distant metastasis (p =0.029) and cancer death (p = 0.001). We found, using the log-rank test, that high NUCB-2 expression was associated with poor disease-free (P < 0.001) and overall survival (P = 0.001). This finding was supported by our results using Cox regression analysis, which showed that NUCB-2 expression was an independent predictor of poor disease-free survival (hazard ratio = 2.63; P = 0.005) and overall survival (hazard ratio = 3.84; P = 0.041).

Conclusion:

NUCB2 might play a crucial role in UTUC development and could serve as an independent predictor of prognosis of UTUC patients.